Effects of inhaled low-concentration xenon gas on naltrexone-precipitated withdrawal symptoms in morphine-dependent mice

• Published in: Drug and alcohol dependence Vol. 255; p. 110967
• Main Authors: Kaufman, Marc J., Meloni, Edward G., Qrareya, Alaa N., Paronis, Carol A., Bogin, Vlad
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.02.2024
• Subjects: Inhalation Therapy; Medications for opioid use disorder; Opioid withdrawal; Sympathetic nervous System; Xenon; Sympathetic nervous System; Medications for opioid use disorder; Inhalation Therapy; Xenon; Opioid withdrawal
• ISSN: 0376-8716; 1879-0046
• DOI: 10.1016/j.drugalcdep.2023.110967

Opioid withdrawal symptoms (OWS) are highly aversive and prompt unprescribed opioid use, which increases morbidity, mortality, and, among individuals being treated for opioid use disorder (OUD), recurrence. OWS are driven by sympathetic nervous system (SNS) hyperactivity that occurs when blood opioid levels wane. We tested whether brief inhalation of xenon gas, which inhibits SNS activity and is used clinically for anesthesia and diagnostic imaging, attenuates naltrexone-precipitated withdrawal-like signs in morphine-dependent mice. Adult CD-1 mice were implanted with morphine sulfate-loaded (60 mg/ml) minipumps and maintained for 6 days to establish morphine dependence. On day 7, mice were given subcutaneous naltrexone (0.3 mg/kg) and placed in a sealed exposure chamber containing either 21% oxygen/balance nitrogen (controls) or 21% oxygen/added xenon peaking at 30%/balance nitrogen. After 10 minutes, mice were transferred to observation chambers and videorecorded for 45 minutes. Videos were scored in a blind manner for morphine withdrawal behaviors. Data were analyzed using 2-way ANOVAs testing for treatment and sex effects. Xenon-exposed mice exhibited fewer jumps (P = 0.010) and jumping suppression was detectible within the first 10-minute video segment, but no sex differences were detected. Brief inhalation of low concentration xenon rapidly and substantially attenuated naltrexone-precipitated jumping in morphine-dependent mice, suggesting that it can inhibit OWS. If xenon effects translate to humans with OUD, xenon inhalation may be effective for reducing OWS, unprescribed opioid use, and for easing OUD treatment initiation, which could help lower excess morbidity and mortality associated with OUD. •Opioid withdrawal symptoms (OWS) trigger unprescribed opioid use.•Unprescribed opioid use increases risks for recurrence, morbidity, and mortality.•We tested effects of inhaled xenon gas (10 min) on OWS in morphine-dependent mice.•Xenon (20% mean concentration) reduced naltrexone-precipitated jumping counts.•Xenon is used clinically for anesthesia & imaging & may be useful for reducing OWS.